Febuxostat for Gout and Hyperuricemia

Title: Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout.
Schumacher HR Jr.
Publication: Expert Opin Investig Drugs. 2005 Jul;14(7):893-903.

Febuxostat is a drug used for the management of hyperuricemia (excessive level of uric acid in the blood) in patients with gout. It is a non-purine, selective inhibitor of an enzyme called xanthine oxidase. This enzyme is involved in the conversion of chemicals to uric acid.

The author reported that 10 to 120 mg/day dose of Feuxostat can produce rapid and sustainable decline in uric acid level in the blood by 25 to 75%, in patients that either over produce uric acid or under-secrete it. This dose seems to be pharmacokinetically linear (i.e. increased dose produce more lowering of uric acid level in a linear fashion), without the need to adjust the dose for those with liver or kidney problems.

When given colchicines or a non-steroidal anti-inflammatory drug in addition to Febuxostat, the risk of gout flare up can be reduced even more. Febuxostat is well tolerated, with only transient mild-to-moderate side effects.

Editor’s note: purine is a group of organic compounds, one member of which is uric acid. Colchicines are a class of drugs used to treat gout.

Main Menu
Health Articles
Health News
Health Research
Site Map

Health Conditions
Cardiovascular Health
Digestive Health
Infectous Diseases
Musculoskeletal Health
Pregnancy & Childbirth
Skin Health

Misc. Health Articles
Presidential Diseases

Medical Research

Gout Overview
Food to Avoid
Research Summaries
Web Resources

©copyright 2004 - Health In Plain English. All Rights Reserved.

Health Articles Health News Health Research Explained in Plain English